Allogene Therapeutics, Inc.
ALLOHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeAllogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. Valued at $749.0M, ALLO is a small-cap name in its sector. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Market Cap
$749.0M
Beta
0.46
P/E (TTM)
—
P/E (Fwd)
-2.82
EPS (TTM)
$-0.77
EPS (Fwd)
$-0.77
ROE
-52.3%
ROA
-26.0%
Cash
$266.9M
Total Debt
$81.1M
Free CF
-$69.9M
52W Change
70.9%
Annual Financials
Cash vs Debt
Allogene Therapeutics, Inc. holds $266.9M in cash against $81.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$69.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -52.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $156K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Allogene Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Allogene Therapeutics, Inc.'s trajectory.